EDGE
Get a demo
Log In

Variantyx

Precision Medicine
Segments:
Genetic Testing
?
Product stage:
Early
?

Variantyx is a precision medicine company offering genetic testing services for rare genetic disorders, reproductive health, and precision oncology. Its proprietary whole-genome sequencing (WGS) and data analysis platform, Genomic Intelligence, identifies unique genetic mutations in a patient’s tumor and predicts treatment response, offering healthcare providers and pharmaceutical companies diagnostics, treatment recommendations, and clinical trial information.  

Its WGS-based approach, which uses multiple genomic technologies, can sequence the entire DNA and this data can be sliced based on the required analysis. It detects multiple types of variants including small sequence changes, large structural variants, mitochondrial variants (common in tumors), and tandem repeat mutations (found in neurological diseases). The company claims this approach allows it to provide insights and analytics that are currently not available through other diagnostic tests at the shortest turnaround time. 

Funding and Financials

The company raised its latest funding in October 2022 amounting to USD 20 million in debt financing from Kreos Capital. This additional finance follows its Series C-2 funding round in February 2022 amounting to USD 41.5 million. The funds were allocated toward expanding its market presence for precision oncology in the US and Europe.

Variantyx secured additional funding in October 2023 from its portfolio of investors, which includes Robert Bosch Venture Capital, Pitango HealthTech, New Era Capital Partners, 20/20 HealthCare Partners, and Peregrine Ventures. The funds raised were expected to be used for commercial expansion. With this, the total amount invested in Variantyx amounted to over USD 120 million.

Precision Medicine

Precision Medicine

Key stats
Featured companies
203
Total funding (USD)
59.2 Bn
Total addressable market (USD)
120.0 Bn
Key competitors
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...

Recent Updates

Product updates
Nov 10, 2023
Variantyx launches IriSight CNV Analysis for chromosomal abnormality detection
Precision Medicine
Funding
Oct 18, 2023
Variantyx secures additional funding from portfolio of investors
Precision Medicine

Company Brief


HQ location:
1671 Worcester Road Suite 300 Framingham MA USA
Founded year:
2014
Employees:
51-100
Total Funding:
USD 100.5 million

Funding


Investors


No investor data is available

Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.